Iambic Therapeutics to Participate in June Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--May 28, 2025--
Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced its participation in the following June investor conferences:
About Iambic's AI-Driven Discovery Platform
The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform's AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence.
About Iambic Therapeutics
Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at Iambic.ai
View source version on businesswire.com:https://www.businesswire.com/news/home/20250528995295/en/
[email protected]
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH TECHNOLOGY CLINICAL TRIALS ARTIFICIAL INTELLIGENCE PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Iambic Therapeutics
Copyright Business Wire 2025.
PUB: 05/28/2025 07:30 AM/DISC: 05/28/2025 07:29 AM
http://www.businesswire.com/news/home/20250528995295/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
4 minutes ago
- Washington Post
04_MONUMENT
RFK Jr. has big plans for your food. Here are the facts. May 2, 2025
Washington Post
16 minutes ago
- Washington Post
‘This is coming for everyone': A new kind of AI bot takes over the web
People are replacing Google search with artificial intelligence tools like ChatGPT, a major shift that has unleashed a new kind of bot loose on the web. To offer users a tidy AI summary instead of Google's '10 blue links,' companies such as OpenAI and Anthropic have started sending out bots to retrieve and recap content in real time. They are scraping webpages and loading relevant content into the AI's memory and 'reading' far more content than a human ever would.
Bloomberg
16 minutes ago
- Bloomberg
Millions of Acres of Public Land Sales Added to Trump's Tax Bill
The sale of millions of acres of federal land would provide billions of dollars to help pay for President Donald Trump's massive package of tax cuts and spending in the Senate's version of the bill released Wednesday night. As much as around 3 million acres of land owned by the Bureau of Land Management and the US Forest Service would be mandated for sale in the legislation. The measure, which requires each agency to sell a small percentage of the hundreds of millions of acres of land they manage in eligible states that include Alaska as well as western states, could raise as much as $10 billion over 10 years, according to a fact sheet.
